FDA designates FF-10832 as an orphan drug for biliary tract cancer, promising enhanced treatment options for this aggressive ...

The analysis showed a 5.8% rate of SPM among 5,517 patients with a median follow-up of 21.7 months. The rate did not vary according to the type of disease treated or the CAR T-cell product used ...

Patients who used dupilumab for atopic dermatitis had significantly lower risks for internal malignancies than patients using other therapies, according to a study published in The Journal of ...

Compared with colorectal cancer (CRC) presenting as an isolated primary or second primary malignancy, CRC presenting as the first of multiple primary malignancies less often presents at advanced stage ...

“FDA has determined that the risk of T-cell malignancies is applicable to all currently approved BCMA-directed and CD19-directed genetically modified autologous CAR T cell immunotherapies.

A study published in Nature reveals the functional relevance of tumor-neuron interactions that regulate the growth of ependymoma brain tumors. The study, conducted by researchers at Baylor College of ...

Second pelvic malignancy -- including bladder and rectum -- rates after brachytherapy were 6.4% at 15 and 9.8% at 20 years. That compared with 3.2% and 4.2% after prostatectomy. The risk of ...